| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Alemtuzumab induction in renal transplantation.
|
N Engl J Med
|
2011
|
4.13
|
|
2
|
Donors with central nervous system malignancies: are they truly safe?
|
Transplantation
|
2003
|
2.12
|
|
3
|
Malignancy after transplantation.
|
Transplantation
|
2005
|
1.92
|
|
4
|
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
|
Transplantation
|
2008
|
1.66
|
|
5
|
Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012.
|
Liver Transpl
|
2014
|
1.63
|
|
6
|
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy.
|
J Virol
|
2006
|
1.58
|
|
7
|
Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy.
|
Am J Transplant
|
2002
|
1.44
|
|
8
|
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis.
|
Transplantation
|
2002
|
1.43
|
|
9
|
Temporary silastic mesh closure for adult liver transplantation: a safe alternative for the difficult abdomen.
|
Liver Transpl
|
2007
|
1.40
|
|
10
|
An initial experience and evolution of laparoscopic hepatic resectional surgery.
|
Surgery
|
2004
|
1.26
|
|
11
|
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population.
|
Transplantation
|
2009
|
1.25
|
|
12
|
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
|
Transplantation
|
2010
|
1.25
|
|
13
|
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death.
|
Transplantation
|
2004
|
1.18
|
|
14
|
Proteasome inhibitor-based therapy for antibody-mediated rejection.
|
Kidney Int
|
2012
|
1.10
|
|
15
|
Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study.
|
Clin Transplant
|
2005
|
1.07
|
|
16
|
Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients.
|
Transplantation
|
2002
|
1.03
|
|
17
|
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
|
Am J Transplant
|
2005
|
1.02
|
|
18
|
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids.
|
Clin Transplant
|
2008
|
1.01
|
|
19
|
Proteasome inhibition for antibody-mediated rejection.
|
Curr Opin Organ Transplant
|
2009
|
1.00
|
|
20
|
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.
|
Transplantation
|
2011
|
0.98
|
|
21
|
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis.
|
Arch Dermatol
|
2011
|
0.97
|
|
22
|
Laparoscopic liver resection.
|
J Am Coll Surg
|
2005
|
0.95
|
|
23
|
Targeting the ubiquitin+proteasome system in solid tumors.
|
Semin Hematol
|
2012
|
0.95
|
|
24
|
Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation.
|
Transplantation
|
2011
|
0.95
|
|
25
|
Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant.
|
Transplantation
|
2004
|
0.94
|
|
26
|
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
|
Transplantation
|
2012
|
0.92
|
|
27
|
Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer.
|
Dis Colon Rectum
|
2004
|
0.92
|
|
28
|
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.
|
J Am Coll Surg
|
2010
|
0.90
|
|
29
|
Basic and clinical research in polyomavirus nephropathy.
|
Exp Clin Transplant
|
2004
|
0.90
|
|
30
|
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience.
|
Am J Transplant
|
2005
|
0.90
|
|
31
|
BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy.
|
J Clin Virol
|
2008
|
0.90
|
|
32
|
Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons.
|
J Plast Reconstr Aesthet Surg
|
2008
|
0.90
|
|
33
|
Desensitization in kidney transplantation: review and future perspectives.
|
Clin Transplant
|
2014
|
0.90
|
|
34
|
Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy.
|
Virology
|
2010
|
0.89
|
|
35
|
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.
|
Clin Transplant
|
2010
|
0.88
|
|
36
|
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.
|
Transplantation
|
2012
|
0.88
|
|
37
|
Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival.
|
Transplantation
|
2015
|
0.87
|
|
38
|
Posttransplant malignancy.
|
Prog Transplant
|
2004
|
0.87
|
|
39
|
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction.
|
Transplantation
|
2017
|
0.87
|
|
40
|
Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry.
|
Transplantation
|
2004
|
0.87
|
|
41
|
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
|
Antioxid Redox Signal
|
2014
|
0.86
|
|
42
|
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
|
Ther Drug Monit
|
2007
|
0.86
|
|
43
|
Impact of recipient morbid obesity on outcomes after liver transplantation.
|
Transpl Int
|
2015
|
0.85
|
|
44
|
Clinical and investigational use of proteasome inhibitors for transplant rejection.
|
Expert Opin Investig Drugs
|
2011
|
0.83
|
|
45
|
A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation.
|
Transplantation
|
2009
|
0.83
|
|
46
|
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy.
|
Transplantation
|
2010
|
0.83
|
|
47
|
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.
|
Am J Transplant
|
2005
|
0.83
|
|
48
|
Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis.
|
HPB (Oxford)
|
2014
|
0.82
|
|
49
|
Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression.
|
Transplantation
|
2005
|
0.81
|
|
50
|
Right donor nephrectomy: a comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches.
|
Transplantation
|
2004
|
0.81
|
|
51
|
Polyomavirus nephropathy in kidney transplantation.
|
Prog Transplant
|
2004
|
0.81
|
|
52
|
Incidental diagnosis of gastric cancer in transplant recipients improves patient survival.
|
Surgery
|
2002
|
0.80
|
|
53
|
Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.
|
Transpl Int
|
2006
|
0.79
|
|
54
|
Malignancy in pediatric transplant recipients.
|
Semin Pediatr Surg
|
2006
|
0.78
|
|
55
|
Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal.
|
Transplantation
|
2013
|
0.78
|
|
56
|
Risk assessment of immunosuppressive therapy in facial transplantation.
|
Plast Reconstr Surg
|
2007
|
0.78
|
|
57
|
Steroid minimization for sirolimus-treated renal transplant recipients.
|
Clin Transplant
|
2010
|
0.78
|
|
58
|
A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
|
Transplantation
|
2015
|
0.78
|
|
59
|
Kidney transplantation: graft monitoring and immunosuppression.
|
World J Surg
|
2001
|
0.78
|
|
60
|
Proteasome inhibition for antibody-mediated allograft rejection.
|
Semin Hematol
|
2012
|
0.77
|
|
61
|
MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature.
|
Transplantation
|
2003
|
0.77
|
|
62
|
The role of immunosuppression in lymphoma.
|
Recent Results Cancer Res
|
2002
|
0.76
|
|
63
|
Transplant recipient's knowledge of posttransplant malignancy risk: implications for educational programs.
|
Transplantation
|
2008
|
0.76
|
|
64
|
Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma.
|
Transplantation
|
2004
|
0.75
|
|
65
|
Management of antibody-mediated rejection in transplantation.
|
Surg Clin North Am
|
2013
|
0.75
|
|
66
|
Syndromic incidence of ovarian cancer after liver transplantation: is breast cancer an antecedent risk?
|
Liver Transpl
|
2004
|
0.75
|
|
67
|
Bortezomib for refractory antibody-mediated cardiac allograft rejection.
|
Clin Transpl
|
2009
|
0.75
|
|
68
|
Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
|
Clin Transpl
|
2009
|
0.75
|
|
69
|
United network for organ sharing publication on scientific registry of transplant recipients central nervous system donor cancer transmission data.
|
Transplantation
|
2005
|
0.75
|
|
70
|
Liver transplantation for primary and metastatic hepatic malignancy: a single center experience.
|
Surgery
|
2006
|
0.75
|
|
71
|
The influence of immunomodulatory diets on transplant success and complications.
|
Transplantation
|
2005
|
0.75
|
|
72
|
The potential of paired donation programs: modeling and reality.
|
Am J Transplant
|
2005
|
0.75
|
|
73
|
The Israel Penn International Transplant Tumor Registry.
|
AMIA Annu Symp Proc
|
2003
|
0.75
|
|
74
|
Surgical techniques in right laparoscopic donor nephrectomy.
|
J Am Coll Surg
|
2002
|
0.75
|
|
75
|
Plasma cell biology: principles for therapeutic design.
|
Clin Transpl
|
2013
|
0.75
|
|
76
|
Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aortorenal junction.
|
Transplantation
|
2003
|
0.75
|
|
77
|
Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant.
|
Exp Clin Transplant
|
2008
|
0.75
|
|
78
|
Can immunonutrients reduce rejection rates in African Americans?
|
Exp Clin Transplant
|
2005
|
0.75
|
|
79
|
Bortezomib-based antibody-mediated rejection therapy and simultaneous conversion to belatacept.
|
Transplantation
|
2014
|
0.75
|